$PPHM News Peregrine plunges on test data 3:17 p
Post# of 44842
Posted On: 12/30/2013 2:39:17 PM
$PPHM News
Peregrine plunges on test data 3:17 p.m. June 27, 2013 - Russ Britt
Small-cap makes a splash with FDA nod for cancer drug 2:16 p.m. May 20, 2013 - Russ Britt
Peregrine drug shows promise in pancreatic cancer 12:17 p.m. Feb. 13, 2013 - MarketWatch.com
In focus: Bullish, but overbought 7:06 p.m. Jan. 9, 2013 - Lawrence G. McMillan
Hedge funds are bullish on these stocks 10:57 a.m. Dec. 5, 2012 - Insider Monkey
Peregrine, FDA agree on brain-cancer drug study 10:56 a.m. Dec. 5, 2012 - MarketWatch.com
Drug trial contractors improve efficiency 9:24 a.m. Nov. 16, 2012 - MarketWatch.com
Monday’s biggest gaining and declining stocks 5:42 p.m. Sept. 25, 2012 - Greg Morcroft
Tuesday’s biggest gaining and declining stocks 4:09 p.m. Sept. 25, 2012 - Greg Morcroft
Peregrine Pharma down 86% after test data review 7:27 a.m. Sept. 24, 2012 - Steve Gelsi
Peregrine Pharma down 86% in premarket 7:18 a.m. Sept. 24, 2012 - Steve Gelsi
Peregrine reviewing Bavituximab results 6:42 a.m. Sept. 24, 2012 - Greg Morcroft
Some previous Bavituximab data not valid
eregrine 6:42 a.m. Sept. 24, 2012 - Greg Morcroft
Monday’s biggest gaining and declining stocks 1:42 p.m. Sept. 10, 2012 - MarketWatch
Regions Financial, Williams-Sonoma hit 52-week highs; Intel, Cisco active 10:11 a.m. Sept. 10, 2012 - blogs.marketwatch.com
Stocks to watch Monday: AIG, Michael Kors, Sears 5:41 a.m. Sept. 10, 2012 - MarketWatch
Peregrine rallies on bavituximab lung-cancer data 12:29 p.m. Sept. 7, 2012 - MarketWatch.com
Monday’s biggest gaining & declining stocks 1:53 p.m. Aug. 27, 2012 - MarketWatch
Peregrine Pharma slides 12% after negative report 1:21 p.m. Aug. 27, 2012 - Val Brickates Kennedy
Monday’s biggest gaining and declining stocks 3:23 p.m. May 21, 2012 - MarketWatch
Peregrine Pharmaceuticals Initiates Sunrise Pivotal Phase III Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer 6:37 a.m. Today - benzinga.com
Consider Buy Rated Stocks Under Five Bucks as Stocking Stuffers 10:28 a.m. Dec. 23, 2013 - TheStreet.com
Peregrine Reports In-Line Loss - Analyst Blog 2:10 p.m. Dec. 11, 2013 - Zacks.com
Peregrine Pharmaceuticals Management Discusses Q2 2014 Results - Earnings Call Transcript 7:20 p.m. Dec. 10, 2013 - Seeking Alpha
10-Q: PEREGRINE PHARMACEUTICALS INC 5:34 p.m. Dec. 10, 2013 - Edgar Online - (EDG = 10Q, 10K)
Peregrine Pharmaceuticals (PPHM) Jumps: Stock Rises 6.2% - Tale of the Tape 9:39 a.m. Nov. 22, 2013 - Zacks.com
The Race For A Cure For Cancer 1:44 p.m. Nov. 20, 2013 - Seeking Alpha
Peregrine's Bavituximab in Combination With Anti-CTLA-4 Antibodies Yields Enhanced Anti-Tumor Activity in Pre-Clinical Model of Melanoma 8:10 a.m. Nov. 8, 2013 - benzinga.com
Peregrine Pharmaceuticals is now in Oversold Territory - Tale of the Tape 7:06 a.m. Nov. 8, 2013 - Zacks.com
2013 Biotech Watchlist Update: Companies Climb And Crumble On Catalysts 10:48 a.m. Nov. 1, 2013 - Seeking Alpha
Peregrine Pharmaceuticals' CEO Hosts Annual Meeting of Stockholders (Transcript) 8:00 p.m. Oct. 17, 2013 - Seeking Alpha
Peregrine Pharmaceuticals, Inc. - Shareholder/Analyst Call 8:00 p.m. Oct. 17, 2013 - Seeking Alpha
Biotech: Let's Make A Billion-Dollar Deal, Part 2 2:00 p.m. Oct. 1, 2013 - Seeking Alpha
Peregrine Pharmaceuticals Earnings: Here’s Why Investors are Not Excited Now 8:58 a.m. Sept. 10, 2013 - Wall St. Cheat Sheet
Peregrine Reports In-Line Loss - Analyst Blog 8:30 a.m. Sept. 10, 2013 - Zacks.com
Peregrine Pharmaceuticals Management Discusses Q1 2014 Results - Earnings Call Transcript 6:10 p.m. Sept. 9, 2013 - Seeking Alpha
10-Q: PEREGRINE PHARMACEUTICALS INC 3:24 p.m. Sept. 9, 2013 - Edgar Online - (EDG = 10Q, 10K)
Encouraging News for Peregrine Pharma - Analyst Blog 4:15 p.m. Aug. 20, 2013 - Zacks.com
9 Compelling Reasons To Buy Opexa Therapeutics Right Now 11:44 a.m. Aug. 15, 2013 - Seeking Alpha
Peregrine Pharmaceuticals: Good Looking, But Still Single 9:27 a.m. July 23, 2013 - Seeking Alpha
Peregrine Pharmaceuticals Initiates Sunrise Pivotal Phase III Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer 7:31 a.m. Today - Marketwire
Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2014 Financial Results and Recent Developments 4:00 p.m. Dec. 10, 2013 - Marketwire
Peregrine Pharmaceuticals Announces Upcoming Events 4:00 p.m. Nov. 26, 2013 - Marketwire
Today's Research: Celgene Corp., Forest Laboratories Inc., Edwards Lifesciences Corp., and Peregrine Pharma Inc. 1:30 p.m. Nov. 22, 2013 - PR Newswire
OXBT, HZNP, PPHM and NWBO added to NASDAQ Healthcare Stock Watch List at GSR 10:35 a.m. Nov. 11, 2013 - ACCESSWIRE
Data Presentation at Society for Immunotherapy of Cancer Annual Meeting Supports Potential of Peregrine Pharmaceuticals' Novel Immunotherapy Bavituximab in Combination With Anti-CTLA-4 Antibodies 9:01 a.m. Nov. 8, 2013 - Marketwire
Peregrine Pharmaceuticals to Present at Credit Suisse 2013 Healthcare Conference 4:00 p.m. Nov. 5, 2013 - Marketwire
Pre-Market Review: Celgene Corp., Forest Laboratories Inc., Peregrine Pharma Inc., and Edwards Lifesciences Corp. 3:03 p.m. Oct. 31, 2013 - PR Newswire
Symposium at IALSC World Conference on Lung Cancer to Highlight Novel Immune Checkpoints Including Peregrine Pharmaceuticals' Bavituximab PS Target 7:31 a.m. Oct. 15, 2013 - Marketwire
Pre-Market Review: Celgene Corp., Forest Laboratories Inc., Peregrine Pharma Inc., and Edwards Lifesciences Corp. 10:25 a.m. Oct. 9, 2013 - PR Newswire
Record Use of At-the-Market (ATM) Offerings by U.S. Life Sciences Companies in First Half of 2013, Reports Brinson Patrick 7:00 a.m. Sept. 17, 2013 - PR Newswire
Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2014 Financial Results and Recent Developments 3:00 p.m. Sept. 9, 2013 - Marketwire
Data Supporting Bavituximab's Immunotherapy Mechanism of Action Published in the Peer-Reviewed AACR Journal Cancer Immunology Research 7:31 a.m. Sept. 9, 2013 - Marketwire
Early Briefing and Review: Celgene Corp., Edwards Lifesciences Corp., Forest Laboratories Inc., and Peregrine Pharma Inc. 4:11 p.m. Sept. 6, 2013 - PR Newswire
Peregrine to Report First Quarter Fiscal Year 2014 Financial Results After Market Close on September 9, 2013 3:06 p.m. Sept. 3, 2013 - Marketwire
Bavituximab's Mechanism of Action Highlighted at Immunomodulatory Therapeutic Antibodies for Cancer Conference 2:01 p.m. Aug. 14, 2013 - Marketwire
Peregrine Pharmaceuticals to Present at Upcoming Conferences 3:00 p.m. Aug. 6, 2013 - Marketwire
Morning Research: Celgene, Edwards Lifesciences, Forest Laboratories, and Peregrine Pharma 8:12 a.m. July 31, 2013 - PR Newswire
Peregrine Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Recent Developments 3:06 p.m. July 11, 2013 - Marketwire
Positive Clinical Data, Marketing Authorizations, and New Appointments Support Growth in Biotech Companies - Research Report on Santarus, VIVUS, Epizyme, Peregrine Pharmaceuticals, and PDL BioPharma 7:00 a.m. July 3, 2013 - PR Newswire
Peregrine plunges on test data 3:17 p.m. June 27, 2013 - Russ Britt
Small-cap makes a splash with FDA nod for cancer drug 2:16 p.m. May 20, 2013 - Russ Britt
Peregrine drug shows promise in pancreatic cancer 12:17 p.m. Feb. 13, 2013 - MarketWatch.com
In focus: Bullish, but overbought 7:06 p.m. Jan. 9, 2013 - Lawrence G. McMillan
Hedge funds are bullish on these stocks 10:57 a.m. Dec. 5, 2012 - Insider Monkey
Peregrine, FDA agree on brain-cancer drug study 10:56 a.m. Dec. 5, 2012 - MarketWatch.com
Drug trial contractors improve efficiency 9:24 a.m. Nov. 16, 2012 - MarketWatch.com
Monday’s biggest gaining and declining stocks 5:42 p.m. Sept. 25, 2012 - Greg Morcroft
Tuesday’s biggest gaining and declining stocks 4:09 p.m. Sept. 25, 2012 - Greg Morcroft
Peregrine Pharma down 86% after test data review 7:27 a.m. Sept. 24, 2012 - Steve Gelsi
Peregrine Pharma down 86% in premarket 7:18 a.m. Sept. 24, 2012 - Steve Gelsi
Peregrine reviewing Bavituximab results 6:42 a.m. Sept. 24, 2012 - Greg Morcroft
Some previous Bavituximab data not valid
eregrine 6:42 a.m. Sept. 24, 2012 - Greg Morcroft Monday’s biggest gaining and declining stocks 1:42 p.m. Sept. 10, 2012 - MarketWatch
Regions Financial, Williams-Sonoma hit 52-week highs; Intel, Cisco active 10:11 a.m. Sept. 10, 2012 - blogs.marketwatch.com
Stocks to watch Monday: AIG, Michael Kors, Sears 5:41 a.m. Sept. 10, 2012 - MarketWatch
Peregrine rallies on bavituximab lung-cancer data 12:29 p.m. Sept. 7, 2012 - MarketWatch.com
Monday’s biggest gaining & declining stocks 1:53 p.m. Aug. 27, 2012 - MarketWatch
Peregrine Pharma slides 12% after negative report 1:21 p.m. Aug. 27, 2012 - Val Brickates Kennedy
Monday’s biggest gaining and declining stocks 3:23 p.m. May 21, 2012 - MarketWatch
Peregrine Pharmaceuticals Initiates Sunrise Pivotal Phase III Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer 6:37 a.m. Today - benzinga.com
Consider Buy Rated Stocks Under Five Bucks as Stocking Stuffers 10:28 a.m. Dec. 23, 2013 - TheStreet.com
Peregrine Reports In-Line Loss - Analyst Blog 2:10 p.m. Dec. 11, 2013 - Zacks.com
Peregrine Pharmaceuticals Management Discusses Q2 2014 Results - Earnings Call Transcript 7:20 p.m. Dec. 10, 2013 - Seeking Alpha
10-Q: PEREGRINE PHARMACEUTICALS INC 5:34 p.m. Dec. 10, 2013 - Edgar Online - (EDG = 10Q, 10K)
Peregrine Pharmaceuticals (PPHM) Jumps: Stock Rises 6.2% - Tale of the Tape 9:39 a.m. Nov. 22, 2013 - Zacks.com
The Race For A Cure For Cancer 1:44 p.m. Nov. 20, 2013 - Seeking Alpha
Peregrine's Bavituximab in Combination With Anti-CTLA-4 Antibodies Yields Enhanced Anti-Tumor Activity in Pre-Clinical Model of Melanoma 8:10 a.m. Nov. 8, 2013 - benzinga.com
Peregrine Pharmaceuticals is now in Oversold Territory - Tale of the Tape 7:06 a.m. Nov. 8, 2013 - Zacks.com
2013 Biotech Watchlist Update: Companies Climb And Crumble On Catalysts 10:48 a.m. Nov. 1, 2013 - Seeking Alpha
Peregrine Pharmaceuticals' CEO Hosts Annual Meeting of Stockholders (Transcript) 8:00 p.m. Oct. 17, 2013 - Seeking Alpha
Peregrine Pharmaceuticals, Inc. - Shareholder/Analyst Call 8:00 p.m. Oct. 17, 2013 - Seeking Alpha
Biotech: Let's Make A Billion-Dollar Deal, Part 2 2:00 p.m. Oct. 1, 2013 - Seeking Alpha
Peregrine Pharmaceuticals Earnings: Here’s Why Investors are Not Excited Now 8:58 a.m. Sept. 10, 2013 - Wall St. Cheat Sheet
Peregrine Reports In-Line Loss - Analyst Blog 8:30 a.m. Sept. 10, 2013 - Zacks.com
Peregrine Pharmaceuticals Management Discusses Q1 2014 Results - Earnings Call Transcript 6:10 p.m. Sept. 9, 2013 - Seeking Alpha
10-Q: PEREGRINE PHARMACEUTICALS INC 3:24 p.m. Sept. 9, 2013 - Edgar Online - (EDG = 10Q, 10K)
Encouraging News for Peregrine Pharma - Analyst Blog 4:15 p.m. Aug. 20, 2013 - Zacks.com
9 Compelling Reasons To Buy Opexa Therapeutics Right Now 11:44 a.m. Aug. 15, 2013 - Seeking Alpha
Peregrine Pharmaceuticals: Good Looking, But Still Single 9:27 a.m. July 23, 2013 - Seeking Alpha
Peregrine Pharmaceuticals Initiates Sunrise Pivotal Phase III Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer 7:31 a.m. Today - Marketwire
Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2014 Financial Results and Recent Developments 4:00 p.m. Dec. 10, 2013 - Marketwire
Peregrine Pharmaceuticals Announces Upcoming Events 4:00 p.m. Nov. 26, 2013 - Marketwire
Today's Research: Celgene Corp., Forest Laboratories Inc., Edwards Lifesciences Corp., and Peregrine Pharma Inc. 1:30 p.m. Nov. 22, 2013 - PR Newswire
OXBT, HZNP, PPHM and NWBO added to NASDAQ Healthcare Stock Watch List at GSR 10:35 a.m. Nov. 11, 2013 - ACCESSWIRE
Data Presentation at Society for Immunotherapy of Cancer Annual Meeting Supports Potential of Peregrine Pharmaceuticals' Novel Immunotherapy Bavituximab in Combination With Anti-CTLA-4 Antibodies 9:01 a.m. Nov. 8, 2013 - Marketwire
Peregrine Pharmaceuticals to Present at Credit Suisse 2013 Healthcare Conference 4:00 p.m. Nov. 5, 2013 - Marketwire
Pre-Market Review: Celgene Corp., Forest Laboratories Inc., Peregrine Pharma Inc., and Edwards Lifesciences Corp. 3:03 p.m. Oct. 31, 2013 - PR Newswire
Symposium at IALSC World Conference on Lung Cancer to Highlight Novel Immune Checkpoints Including Peregrine Pharmaceuticals' Bavituximab PS Target 7:31 a.m. Oct. 15, 2013 - Marketwire
Pre-Market Review: Celgene Corp., Forest Laboratories Inc., Peregrine Pharma Inc., and Edwards Lifesciences Corp. 10:25 a.m. Oct. 9, 2013 - PR Newswire
Record Use of At-the-Market (ATM) Offerings by U.S. Life Sciences Companies in First Half of 2013, Reports Brinson Patrick 7:00 a.m. Sept. 17, 2013 - PR Newswire
Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2014 Financial Results and Recent Developments 3:00 p.m. Sept. 9, 2013 - Marketwire
Data Supporting Bavituximab's Immunotherapy Mechanism of Action Published in the Peer-Reviewed AACR Journal Cancer Immunology Research 7:31 a.m. Sept. 9, 2013 - Marketwire
Early Briefing and Review: Celgene Corp., Edwards Lifesciences Corp., Forest Laboratories Inc., and Peregrine Pharma Inc. 4:11 p.m. Sept. 6, 2013 - PR Newswire
Peregrine to Report First Quarter Fiscal Year 2014 Financial Results After Market Close on September 9, 2013 3:06 p.m. Sept. 3, 2013 - Marketwire
Bavituximab's Mechanism of Action Highlighted at Immunomodulatory Therapeutic Antibodies for Cancer Conference 2:01 p.m. Aug. 14, 2013 - Marketwire
Peregrine Pharmaceuticals to Present at Upcoming Conferences 3:00 p.m. Aug. 6, 2013 - Marketwire
Morning Research: Celgene, Edwards Lifesciences, Forest Laboratories, and Peregrine Pharma 8:12 a.m. July 31, 2013 - PR Newswire
Peregrine Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Recent Developments 3:06 p.m. July 11, 2013 - Marketwire
Positive Clinical Data, Marketing Authorizations, and New Appointments Support Growth in Biotech Companies - Research Report on Santarus, VIVUS, Epizyme, Peregrine Pharmaceuticals, and PDL BioPharma 7:00 a.m. July 3, 2013 - PR Newswire
(0)
(0)Scroll down for more posts ▼